Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bruker’s ultrafleXtreme™ MALDI-TOF/TOF to be Coupled with Nextval’s MassInsight™ Technology

Published: Monday, February 11, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Collaboration between Bruker and Nextval for high-throughput screening of drugs.

Bruker has announced a collaboration between Bruker and Nextval for high-throughput screening of drugs and their metabolites using Bruker's ultrafleXtreme MALDI-TOF/TOF in conjunction with Nextval's MassInsight technology.

The ultrafleXtreme mass spectrometer combines the acquisition speed of its 2 kHz smartbeam II™ laser with its Perpetual Ion Source for unrivalled productivity, ensuring optimum performance for low concentration high-throughput screening.

The versatility of Bruker's Compass™ software allows integration with Nextval's screening technology to maximize sample density and reduce sample analysis costs.

Nextval's MassInsight screening technology is based on novel surface chemistries coupled with unique microarray acoustic deposition methods (EDC Biosystems & BioSero LLC) that address critical needs in several industries including the pharmaceutical, testing and industrial markets.

Dr. Matthew Greving, CSO of Nextval, stated: "The ultrafleXtreme is an invaluable tool for Nextval because it combines the sensitivity and throughput needed for our MassInsight customers, enabling fast accurate screening of potential drug candidates and enzyme activity."

Nextval recently has been awarded a Phase II SBIR grant to further develop and commercialize their MassInsight technology for high-throughput enzyme assays.

Dr. Paul Speir, Senior Vice President of Bruker Daltonics stated: "We are excited by the combination of Nextval's MassInsight technology with the information rich, high throughput capabilities provided by the ultrafleXtreme. Moreover, we are pleased to support Nextval in their efforts to develop this important technology for the rapid and economical screening of drug candidates."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker Awarded Fourth PeakForce Tapping Patent
AFM mode uniquely combines highest resolution imaging and material property mapping.
Thursday, July 24, 2014
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker Celebrates Double Award Win at Pittcon 2012
The new GC-MS platform from Bruker Chemical and Applied Markets (CAM) Division – SCION TQ™ – picked up two prestigious awards at last week’s Pittcon in Orlando, Florida.
Tuesday, March 20, 2012
Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos